Immune thrombocytopenic purpura (ITP). Immune thrombocytopenic purpura
Conditions
Interventions
Intervention 1: Intervention group: group receiving intravenous immunoglobulin: In this group, participants receive intravenous immunoglobulin at a dose of 0.8 mg per kilogram of the patient's weight
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
1 Months to 17 Years
Inclusion criteria
Inclusion criteria: Age of participants between one month and 17 years diagnosis of ITP The patient's plasma platelets are less than 10,000 per deciliter
Exclusion criteria
Exclusion criteria: Life-threatening bleeding History of splenectomy Any contraindications for receiving IVIG A history of receiving IVIG or corticosteroids in the last two weeks (platelets have not reached more than 50,000) Presence of co-morbidity such as sepsis Fever above 38.5 degrees Celsius Splenomegaly (the edge of the spleen two centimeters below the edge of the rib) Presence of disseminated intravascular coagulation (DIC) (i.e., fibrinogen < 1 along with elevated D-dimer)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Platelet count. Timepoint: The platelet count will be measured within three intervals: 48 hours, 7 days and one month after IVIG injection. Method of measurement: Cell blood count. | — |
Secondary
| Measure | Time frame |
|---|---|
| Bleeding symptoms. Timepoint: During hospitalization. Method of measurement: Questionnaire and physical examination by pediatric hematologist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoud Khodaei
Shahid Beheshti University of Medical Sciences
Outcome results
None listed